Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | APEX1 | P27695 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140338 | 1.00 | ADRB2 (0.56) | ADRB2PDE2AACACBCYP1A2CYP2D6 | |
| SCHEMBL9395164 | 1.00 | ADRB2 (0.56) | ADRB2PDE2AACACBCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL22345010 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AACACBCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL31430963 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AACACBCYP1A2CYP2D6 | |
| Bromide SCHEMBL25272003 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AACACBCYP1A2CYP2D6 | |
| SCHEMBL1314596 | 0.85 | ADRB2 (0.72) | ADRB2PDE2AROCK2ROCK1APEX1 | |
| SCHEMBL11086725 | 0.79 | DPP4 (0.36) | ADRB2ACACBCYP1A2CYP2D6APEX1 | |
| SCHEMBL672518 | 0.77 | ESR1 (0.52) | ADRB2ACACBCYP1A2CYP2D6APEX1 | |
| SCHEMBL10714 | 0.77 | TYR (0.46) | ACACBCYP1A2CYP2D6IDO1KDM4E | |
| SCHEMBL17540834 | 0.77 | ADRB2 (0.70) | ADRB2PDE2ACYP2D6IDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2797884-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2516009-B1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8623860-B2 | Azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623860-B2 | Azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623860-B2 | Azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| CN-102770182-A | Substituted isoquinolinones and quinazolinones | NOVARTIS AG | 2012-11-07 | — | — | CN | disclosed |
| EP-2516009-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | ADRB2 3626/4885PDE2A 4314/4885ACACB 3703/4885 |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | QDPR, AZI2, CYP2C19 | ADRB2 67/4885PDE2A 14/4885ACACB 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.